Analysts Set Expectations for RCKT Q1 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a report released on Thursday, February 27th. William Blair analyst S. Corwin forecasts that the biotechnology company will earn ($0.27) per share for the quarter. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. William Blair also issued estimates for Rocket Pharmaceuticals' Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.25 EPS and FY2026 earnings at ($0.04) EPS.

RCKT has been the topic of several other research reports. Canaccord Genuity Group dropped their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a research note on Monday. Wedbush initiated coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They set an "outperform" rating and a $32.00 price target for the company. Jefferies Financial Group started coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price objective on the stock. Leerink Partners dropped their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 19th. Finally, Scotiabank lifted their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $42.30.

Remove Ads

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock traded down $0.20 on Monday, reaching $9.02. The stock had a trading volume of 300,593 shares, compared to its average volume of 1,421,385. Rocket Pharmaceuticals has a 12 month low of $8.25 and a 12 month high of $28.73. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $821.78 million, a price-to-earnings ratio of -3.28 and a beta of 0.98. The firm's 50-day moving average is $10.73 and its two-hundred day moving average is $14.48.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RCKT. Covestor Ltd boosted its stake in shares of Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after buying an additional 1,990 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Rocket Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 582 shares in the last quarter. Signaturefd LLC lifted its position in shares of Rocket Pharmaceuticals by 319.8% during the 4th quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 3,745 shares during the period. Harbour Investments Inc. grew its holdings in shares of Rocket Pharmaceuticals by 51.9% during the 4th quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after purchasing an additional 1,840 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 3,366 shares during the period. Institutional investors and hedge funds own 98.39% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.